Secure Asset Management LLC Has $824,000 Position in Pfizer Inc. (NYSE:PFE)

Secure Asset Management LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 63.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,501 shares of the biopharmaceutical company’s stock after selling 55,373 shares during the quarter. Secure Asset Management LLC’s holdings in Pfizer were worth $824,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. D Orazio & Associates Inc. grew its position in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 391 shares in the last quarter. Lipe & Dalton grew its holdings in Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 400 shares in the last quarter. Beam Wealth Advisors Inc. grew its holdings in Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after acquiring an additional 401 shares in the last quarter. Providence Capital Advisors LLC increased its position in Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after purchasing an additional 409 shares during the period. Finally, Donaldson Capital Management LLC raised its holdings in shares of Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after purchasing an additional 410 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.3%

Shares of PFE stock opened at $23.42 on Thursday. The stock’s fifty day moving average price is $23.02 and its 200 day moving average price is $25.02. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market cap of $133.15 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter last year, the company posted $0.82 earnings per share. The business’s quarterly revenue was down 7.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.34%. Pfizer’s dividend payout ratio is currently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.